CA1163556A - Vaccine for infectious bovine rhinotracheitis - Google Patents

Vaccine for infectious bovine rhinotracheitis

Info

Publication number: CA1163556A
Authority: CA; Canada
Prior art keywords: virus; ibr; vaccine; vaccines; protein
Prior art date: 1979-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000355701A

Other languages

English (en)

French (fr)

Inventor

Harold W. Lupton

David E. Reed

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Iowa State University Research Foundation Inc ISURF

Original Assignee

Iowa State University Research Foundation Inc ISURF

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-07-09

Filing date

1980-07-08

Publication date

1984-03-13

1980-07-08 Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF

1984-03-13 Application granted granted Critical

1984-03-13 Publication of CA1163556A publication Critical patent/CA1163556A/en

Status Expired legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 51
208000005562 infectious bovine rhinotracheitis Diseases 0.000 title claims abstract 8
241000700605 Viruses Species 0.000 claims abstract description 44
239000003599 detergent Substances 0.000 claims abstract description 16
108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract description 8
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000623 proteins and genes Proteins 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 11
230000000890 antigenic effect Effects 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
239000007864 aqueous solution Substances 0.000 claims description 8
239000012528 membrane Substances 0.000 claims description 5
239000000243 solution Substances 0.000 claims description 5
230000001413 cellular effect Effects 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 3
230000001902 propagating effect Effects 0.000 claims description 2
239000002671 adjuvant Substances 0.000 abstract description 15
241001465754 Metazoa Species 0.000 abstract description 8
238000000605 extraction Methods 0.000 abstract description 6
230000005875 antibody response Effects 0.000 abstract description 3
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 24
241000283690 Bos taurus Species 0.000 description 23
238000002255 vaccination Methods 0.000 description 21
244000309466 calf Species 0.000 description 17
239000002609 medium Substances 0.000 description 17
201000010099 disease Diseases 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
239000012894 fetal calf serum Substances 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
230000028327 secretion Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 7
229940031626 subunit vaccine Drugs 0.000 description 7
239000000284 extract Substances 0.000 description 6
239000002054 inoculum Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000726306 Irus Species 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
238000006386 neutralization reaction Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
229920000936 Agarose Polymers 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002955 isolation Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
229920004890 Triton X-100 Polymers 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000005265 lung cell Anatomy 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
238000012770 revaccination Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
239000006145 Eagle's minimal essential medium Substances 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
208000032420 Latent Infection Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000018569 Respiratory Tract disease Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
206010000210 abortion Diseases 0.000 description 2
231100000176 abortion Toxicity 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
229960002064 kanamycin sulfate Drugs 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
238000000527 sonication Methods 0.000 description 2
229960002385 streptomycin sulfate Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000010414 supernatant solution Substances 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010004078 Balanoposthitis Diseases 0.000 description 1
241000283725 Bos Species 0.000 description 1
241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
241000030939 Bubalus bubalis Species 0.000 description 1
241001269524 Dura Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
206010051497 Rhinotracheitis Diseases 0.000 description 1
101100467517 Schizosaccharomyces pombe (strain 972 / ATCC 24843) raf2 gene Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
206010044302 Tracheitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
210000003128 head Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
238000005185 salting out Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
208000010484 vulvovaginitis Diseases 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA000355701A 1979-07-09 1980-07-08 Vaccine for infectious bovine rhinotracheitis Expired CA1163556A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5582179A	1979-07-09	1979-07-09
US55,821		1979-07-09

Publications (1)

Publication Number	Publication Date
CA1163556A true CA1163556A (en)	1984-03-13

Family

ID=22000364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000355701A Expired CA1163556A (en)	1979-07-09	1980-07-08	Vaccine for infectious bovine rhinotracheitis

Country Status (6)

Country	Link
CA (1)	CA1163556A (da)
DE (1)	DE3026044A1 (da)
DK (1)	DK276380A (da)
FR (1)	FR2460676A1 (da)
GB (1)	GB2052983B (da)
NL (1)	NL8003889A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2221040C1 (ru) *	2002-06-28	2004-01-10	Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных	Штамм "вниизж" вируса инфекционного ринотрахеита крупного рогатого скота для изготовления вакцинных и диагностических препаратов
ES2991988T3 (es)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1486557A (en) *	1973-10-18	1977-09-21	Flockhart & Co	Process for the preparation of pyrogen-free sub-unit vaccine

1980
- 1980-06-26 DK DK276380A patent/DK276380A/da not_active Application Discontinuation
- 1980-06-30 GB GB8021393A patent/GB2052983B/en not_active Expired
- 1980-07-03 FR FR8014845A patent/FR2460676A1/fr not_active Withdrawn
- 1980-07-04 NL NL8003889A patent/NL8003889A/nl not_active Application Discontinuation
- 1980-07-08 CA CA000355701A patent/CA1163556A/en not_active Expired
- 1980-07-09 DE DE19803026044 patent/DE3026044A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
FR2460676A1 (fr)	1981-01-30
GB2052983A (en)	1981-02-04
NL8003889A (nl)	1981-01-13
DK276380A (da)	1981-01-10
GB2052983B (en)	1983-09-21
DE3026044A1 (de)	1981-02-05

Legal Events

Date	Code	Title	Description
2001-03-13	MKEX	Expiry

Publication	Publication Date	Title
Lupton et al.	1980	Evaluation of experimental subunit vaccines for infectious bovine rhinotracheitis
CA1045546A (en)	1979-01-02	Highly attenuated cytomegalovirus vaccine and production thereof
DK162421B (da)	1991-10-28	Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen
Plowright	1984	The duration of immunity in cattle following inoculation of rinderpest cell culture vaccine
Inaba et al.	1968	Bovine epizootic fever I. Propagation of the virus in suckling hamster, mouse and rat, and hamster kidney BHK21-WI2 cell
CA1184115A (en)	1985-03-19	Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines
US4291019A (en)	1981-09-22	Vaccine for infectious bovine rhinotracheitis
US4571386A (en)	1986-02-18	Feline infectious peritonitis vaccine
EP0975360B1 (en)	2006-08-02	Bovine respiratory and enteric coronovirus as a vaccine
WO1998040097A9 (en)	1999-02-25	Bovine respiratory and enteric coronavirus as a vaccine
US3479430A (en)	1969-11-18	Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same
CA1163556A (en)	1984-03-13	Vaccine for infectious bovine rhinotracheitis
RU2699671C1 (ru)	2019-09-09	Вакцина для ранней защиты против ящура типа О инактивированная эмульсионная
US3000788A (en)	1961-09-19	Propagation of modified infectious canine hepatitis virus in tissue cultures of pig kidney and the preparation of a vaccine therefrom
Hirano et al.	1986	Replication of sialodacryoadenitis virus of rat in LBC cell culture
US3585108A (en)	1971-06-15	Transmissible gastroenteritis vaccines and methods of producing the same
EP0011865B1 (en)	1982-05-19	Feline infectious peritonitis vaccine and process for its preparation
NZ226353A (en)	1991-07-26	Feline infectious peritonitus (fip) vaccine
Tan et al.	1971	Further studies on feline respiratory virus diseases: 1. Vaccination experiments
RU2204599C1 (ru)	2003-05-20	Штамм № 1734 "приморский-2000" вируса ящура типа о для изготовления диагностических и вакцинных препаратов
Gough et al.	1983	A viral subunit immunogen for porcine transmissible gastroenteritis
CA1151546A (en)	1983-08-09	Specific antigen vaccine for tge in swine
Allam et al.	2012	Use of rabbits as a laboratory model for evaluation of the combined inactivated respiratory virus vaccine (Pneumo-3) adjuvanted by Montanide oil (ISA 206)
RU2218397C1 (ru)	2003-12-10	Штамм № 1737/грузия/2000 вируса ящура типа азия-1 для изготовления диагностических и вакцинных препаратов
RU2045960C1 (ru)	1995-10-20	Вакцина для профилактики чумы, инфекционного гепатита, аденовироза, парвовирусного энтерита и лептоспироза собак